Anticorps Recombinant de lapin anti-PCSK9

PCSK9 Recombinant Antibody for WB, IF/ICC, FC (Intra), Sandwich ELISA, Indirect ELISA, Sample test

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IF/ICC, FC (Intra), Sandwich ELISA, Indirect ELISA, Sample test

Conjugaison

Non conjugué

CloneNo.

241395G1

N° de cat : 84172-4-PBS

Synonymes

241395G1, EC:3.4.21.-, FH3, HCHOLA3, LDLCQ1

---

Galerie de données de validation

• 

  WB analysis of HepG2 using 84172-4-RR (same clone as 84172-4-PBS)

  HepG2 cells were subjected to SDS PAGE followed by western blot with 84172-4-RR (PCSK9 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 84172-4-PBS in a different storage buffer formulation.

• 

  Sandwich ELISA standard curve of MP01071-4

  Sandwich ELISA standard curve of MP01071-4, Human PCSK9 Recombinant Matched Antibody Pair - PBS only. 84172-4-PBS was coated to a plate as the capture antibody and incubated with serial dilutions of standard Eg0362. 84172-6-PBS was HRP conjugated as the detection antibody. Range: 195-6250 pg/mL.

• 

  Sample test of MP01071-4

  Plasma of six individual healthy human donors was measured. The PCSK9 concentration of detected samples was determined to be 206.0 ng/mL with a range of ND-514.5 ng/mL.

• 

  Sample test of MP01071-4

  HepG2 were cultured in DMEM supplemented with 10% fetal bovine serum, 2.5 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin sulfate. An aliquot of the cell culture supernate was removed, assayed for human PCSK9, and measured 81.6 ng/mL.

• 

  Sample test of MP01071-4

  The mean PCSK9 concentration was determined to be 6.6 ng/mL in HepG2 cell extract based on a 2.0 mg/mL extract load.

• 

  Sample test of MP01071-4

  Serum of six individual healthy human donors was measured. The PCSK9 concentration of detected samples was determined to be 120.8 ng/mL with a range of ND-421.1 ng/mL.

• 

  IF Staining of HepG2 using 84172-4-RR (same clone as 84172-4-PBS)

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using PCSK9 antibody (84172-4-RR, Clone: 241395G1 ) at dilution of 1:400 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2), CL594-Phalloidin (red). This data was developed using the same antibody clone with 84172-4-PBS in a different storage buffer formulation.

• 

  FC experiment of HeLa using 84172-4-RR (same clone as 84172-4-PBS)

  1x10^6 HeLa cells were intracellularly stained with 0.25 ug PCSK9 Recombinant antibody (84172-4-RR, Clone:241395G1) and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2)(red), or 0.25 ug Rabbit IgG Isotype Control RecAb (98136-1-RR, Clone: 240953C9) (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C). This data was developed using the same antibody clone with 84172-4-PBS in a different storage buffer formulation.

• 

  Affinity and Kinetic Characterization of 84172-4-RR

  Biolayer interferometry (BLl) kinetic assays of 84172-4-RR against Human PCSK9 were performed. The affinity constant is 0.80 nM.

---

Informations sur le produit

84172-4-PBS cible PCSK9 dans les applications de WB, IF/ICC, FC (Intra), Sandwich ELISA, Indirect ELISA, Sample test et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: PCSK9 Protéine recombinante Eg0362
• Nom complet: proprotein convertase subtilisin/kexin type 9
• Masse moléculaire calculée: 74 kDa
• Poids moléculaire observé: 72-78 kDa, 62 kDa
• Numéro d’acquisition GenBank: NM_174936.4
• Symbole du gène: PCSK9
• Identification du gène (NCBI): 255738
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

{{ptg:RelatedPrimaryAntibodies}}